We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Healthcare Inv | LSE:HIO | London | Ordinary Share | GB00B94T6Y14 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 14.75 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
05/1/2014 15:53 | HIO now moved to COS | cnx | |
02/1/2014 15:46 | Sorry I can't Mirabeau as I'm not a subscriber! I've set up a new thread on M----am. :-) | doodlebug4 | |
02/1/2014 14:22 | Set one up ffs! | mirabeau | |
02/1/2014 14:21 | No new thread as yet, latifs. The new epic is COS. | doodlebug4 | |
02/1/2014 12:13 | this is now called collagen solutions. is here a new thread? | latifs100 | |
30/12/2013 14:29 | From an article in the Daily Mail published 31st July. Flotation was in April. "At the time of HIO's flotation Evans was granted options over 4.05million shares (10 per cent of the equity), which will only vest in the event that an acquisition is completed within 12 months from admission, and if the share price is in excess of 20p per share. Once vested, the exercise period of the options will be 10 years and the exercise price will be 10p per share. Evans has a big City fan club and it is easy to see why. The companies under his stewardship have a strong record of value generation for shareholders. He was chief executive of Shield Diagnostics prior to the merger with Axis Biochemicals to form Axis Shield in 1999. He was also chairman of Immunodiagnostic Systems, which floated in December 2004 at 51p and was trading at 1046p at the time he left the company in September 2011." | doodlebug4 | |
27/12/2013 15:32 | Director Shareholding RNS RNS Number : 4668W Healthcare Investment Opportunities 27 December 2013 27 December 2013 Healthcare Investment Opportunities Plc (the "Company") Director Shareholding Healthcare Investment Opportunities plc (AIM: HIO), an investment company focusing on the healthcare sector, announces that today Malcolm Gillies, a Director of Healthcare Investment Opportunities, has purchased a total of 250,000 ordinary shares at an average price of 12.789 pence per share. This brings Malcolm Gillies' interest in the Company's current issued share capital to 500,000 being 1.24% of the current issued share capital. | doodlebug4 | |
13/12/2013 12:40 | David Evans has a pretty impressive track record. Nice little delayed trade just gone through. | doodlebug4 | |
11/12/2013 08:36 | rivaldo, tend to agree with you. Will carry on watching from the sidelines. | 127tolmers | |
10/12/2013 15:59 | Been following this one for a while without buying, but I must say I find today's acquisition most uninspiring/disappoi Quite happy to be put right, but it seems the market agrees with me so far. | rivaldo | |
29/11/2013 06:02 | It is well past the six months timescale predicted in the prospectus ,perhaps we will hear soon some news | wingrove4 | |
26/11/2013 15:48 | Something stirring here at last? | doodlebug4 | |
17/10/2013 15:06 | I am a little frustrated no news and well past 6 months. Still they say no news is good news | 4wingrove | |
06/9/2013 08:30 | Nice tick up again this morning. | doodlebug4 | |
06/9/2013 08:28 | Further tick up this morning, and looking like is all buys | master rsi | |
05/9/2013 18:56 | Large late buy at 15. Presumably these swings follow potential investments brewing and then fading. Something probably brewing | ade45 | |
05/9/2013 14:12 | Admitted to AIM on 10th April so the clock is ticking now and not long left until the six months is up. "The Board, through its extensive network of contacts, has identified a number of potentially interesting investment opportunities, although formal discussions in respect of any of these opportunities have not yet commenced. The Board anticipates the first acquisition will be a reverse takeover, in accordance with the AIM Rules for Companies, will be subject to prior shareholder approval and the publication of an admission Document and is expected to be made within 6 months of Admission. In addition, the Board may also consider making other smaller acquisitions or investments although the Directors do not intend to create a portfolio of unconnected companies." | doodlebug4 | |
05/9/2013 14:09 | Something's beginning to bubble here, I agree Master RSI. | doodlebug4 | |
05/9/2013 14:06 | Bouncing after retracement, some large buys for the last couple days and Market Makers looking like short of stock | master rsi | |
31/7/2013 16:02 | Delayed trades put through this afternoon, I suppose some of the people who bought in at the original float price in April might be happy to cash in on their profit. I'm happy to wait this one out, even if it takes 7 years for David Evans to put in a similar performance to the one when he was chairman of Immundiagnostic Systems ! | doodlebug4 | |
31/7/2013 14:09 | Buyers paying the full offer price of 17p now. | doodlebug4 | |
31/7/2013 12:22 | Evans is a respected figure in the City. His credentials are impeccable but this stock's speculative but if anyone's got the expertise and experience to succeed then Evans surely has | mirabeau | |
31/7/2013 12:18 | I like the last sentence of that article in the Daily Mail - referring to David Evans. He's certainly got a good CV ! "He was also chairman of Immunodiagnostic Systems, which floated in December 2004 at 51p and was trading at 1046p at the time he left the company in September 2011." | doodlebug4 | |
31/7/2013 11:18 | I've just bought a few tpinvest, whether or not the hot gossip turns out to be accurate it would appear that David Evans has a good track record - so this is worth a punt imo. | doodlebug4 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions